Distinct IPS Cells Show Different Cardiac Differentiation Efficiency

Overview

Journal Stem Cells Int

Publisher Wiley

Specialty Cell Biology

Date 2013 Dec 25

PMID 24367382

Citations 9

Authors

Yohei Ohno

Shinsuke Yuasa

Toru Egashira

Tomohisa Seki

Hisayuki Hashimoto

Shugo Tohyama

Yuki Saito

Akira Kunitomi

Kenichiro Shimoji

Takeshi Onizuka

Toshimi Kageyama

Kojiro Yae

Tomofumi Tanaka

Ruri Kaneda

Fumiyuki Hattori

Mitsushige Murata

Kensuke Kimura

Keiichi Fukuda

Affiliations

Soon will be listed here.

Abstract

Patient-specific induced pluripotent stem (iPS) cells can be generated by introducing transcription factors that are highly expressed in embryonic stem (ES) cells into somatic cells. This opens up new possibilities for cell transplantation-based regenerative medicine by overcoming the ethical issues and immunological problems associated with ES cells. Despite the development of various methods for the generation of iPS cells that have resulted in increased efficiency, safety, and general versatility, it remains unknown which types of iPS cells are suitable for clinical use. Therefore, the aims of the present study were to assess (1) the differentiation potential, time course, and efficiency of different types of iPS cell lines to differentiate into cardiomyocytes in vitro and (2) the properties of the iPS cell-derived cardiomyocytes. We found that high-quality iPS cells exhibited better cardiomyocyte differentiation in terms of the time course and efficiency of differentiation than low-quality iPS cells, which hardly ever differentiated into cardiomyocytes. Because of the different properties of the various iPS cell lines such as cardiac differentiation efficiency and potential safety hazards, newly established iPS cell lines must be characterized prior to their use in cardiac regenerative medicine.

Citing Articles

Optimization of H9c2 differentiation leads to calcium-active and striated cardiac cells without addition of retinoic acid.

Brock J, Horning M Front Cell Dev Biol. 2024; 12:1501540.

PMID: 39650723 PMC: 11621855. DOI: 10.3389/fcell.2024.1501540.

Detection of biomagnetic signals from induced pluripotent stem cell-derived cardiomyocytes using deep learning with simulation data.

Yamaguchi T, Adachi Y, Tanida T, Taguchi K, Oka Y, Yoshida T Sci Rep. 2024; 14(1):7296.

PMID: 38538741 PMC: 10973465. DOI: 10.1038/s41598-024-58010-0.

Evaluation of Pancreatic β-cell Differentiation Efficiency of Human iPSC Lines for Clinical Use.

Horikawa A, Tsuda K, Yamamoto T, Michiue T Curr Stem Cell Res Ther. 2024; 19(11):1449-1460.

PMID: 38311917 DOI: 10.2174/011574888X267226231126185532.

Action potential variability in human pluripotent stem cell-derived cardiomyocytes obtained from healthy donors.

Carvalho A, Coutinho K, Barbosa R, de Campos D, Leitao I, Pinto R Front Physiol. 2023; 13:1077069.

PMID: 36589430 PMC: 9800870. DOI: 10.3389/fphys.2022.1077069.

A call to adopt a "fit for purpose" approach to antibody validation for flow cytometry analyses of stem cell models and beyond.

Waas M, Gundry R Am J Physiol Heart Circ Physiol. 2019; 317(5):H954-H957.

PMID: 31559827 PMC: 6879911. DOI: 10.1152/ajpheart.00347.2019.

References

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K . Variation in the safety of induced pluripotent stem cell lines. Nat Biotechnol. 2009; 27(8):743-5. DOI: 10.1038/nbt.1554. View

Chen H, Hattori F, Murata M, Li W, Yuasa S, Onizuka T . Common marmoset embryonic stem cell can differentiate into cardiomyocytes. Biochem Biophys Res Commun. 2008; 369(3):801-6. DOI: 10.1016/j.bbrc.2008.02.141. View

Kuzmenkin A, Liang H, Xu G, Pfannkuche K, Eichhorn H, Fatima A . Functional characterization of cardiomyocytes derived from murine induced pluripotent stem cells in vitro. FASEB J. 2009; 23(12):4168-80. DOI: 10.1096/fj.08-128546. View

Aoi T, Yae K, Nakagawa M, Ichisaka T, Okita K, Takahashi K . Generation of pluripotent stem cells from adult mouse liver and stomach cells. Science. 2008; 321(5889):699-702. DOI: 10.1126/science.1154884. View

Ye Z, Zhan H, Mali P, Dowey S, Williams D, Jang Y . Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disorders. Blood. 2009; 114(27):5473-80. PMC: 2798863. DOI: 10.1182/blood-2009-04-217406. View

Zhou H, Wu S, Joo J, Zhu S, Han D, Lin T . Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell. 2009; 4(5):381-4. PMC: 10182564. DOI: 10.1016/j.stem.2009.04.005. View

Xi J, Khalil M, Shishechian N, Hannes T, Pfannkuche K, Liang H . Comparison of contractile behavior of native murine ventricular tissue and cardiomyocytes derived from embryonic or induced pluripotent stem cells. FASEB J. 2010; 24(8):2739-51. DOI: 10.1096/fj.09-145177. View

Fusaki N, Ban H, Nishiyama A, Saeki K, Hasegawa M . Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. Proc Jpn Acad Ser B Phys Biol Sci. 2009; 85(8):348-62. PMC: 3621571. DOI: 10.2183/pjab.85.348. View

10.

Woltjen K, Michael I, Mohseni P, Desai R, Mileikovsky M, Hamalainen R . piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature. 2009; 458(7239):766-70. PMC: 3758996. DOI: 10.1038/nature07863. View

11.

Okita K, Ichisaka T, Yamanaka S . Generation of germline-competent induced pluripotent stem cells. Nature. 2007; 448(7151):313-7. DOI: 10.1038/nature05934. View

12.

Hotta A, Ellis J . Retroviral vector silencing during iPS cell induction: an epigenetic beacon that signals distinct pluripotent states. J Cell Biochem. 2008; 105(4):940-8. DOI: 10.1002/jcb.21912. View

13.

Kaichi S, Hasegawa K, Takaya T, Yokoo N, Mima T, Kawamura T . Cell line-dependent differentiation of induced pluripotent stem cells into cardiomyocytes in mice. Cardiovasc Res. 2010; 88(2):314-23. DOI: 10.1093/cvr/cvq189. View

14.

Kim J, Greber B, Arauzo-Bravo M, Meyer J, Park K, Zaehres H . Direct reprogramming of human neural stem cells by OCT4. Nature. 2009; 461(7264):649-3. DOI: 10.1038/nature08436. View

15.

Thomson J, Itskovitz-Eldor J, Shapiro S, Waknitz M, Swiergiel J, Marshall V . Embryonic stem cell lines derived from human blastocysts. Science. 1998; 282(5391):1145-7. DOI: 10.1126/science.282.5391.1145. View

16.

Eminli S, Foudi A, Stadtfeld M, Maherali N, Ahfeldt T, Mostoslavsky G . Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells. Nat Genet. 2009; 41(9):968-76. PMC: 3987895. DOI: 10.1038/ng.428. View

17.

Wernig M, Meissner A, Foreman R, Brambrink T, Ku M, Hochedlinger K . In vitro reprogramming of fibroblasts into a pluripotent ES-cell-like state. Nature. 2007; 448(7151):318-24. DOI: 10.1038/nature05944. View

18.

Evans M, Kaufman M . Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981; 292(5819):154-6. DOI: 10.1038/292154a0. View

19.

Zhou W, Freed C . Adenoviral gene delivery can reprogram human fibroblasts to induced pluripotent stem cells. Stem Cells. 2009; 27(11):2667-74. DOI: 10.1002/stem.201. View

20.

Egashira T, Yuasa S, Fukuda K . Induced pluripotent stem cells in cardiovascular medicine. Stem Cells Int. 2011; 2011:348960. PMC: 3184500. DOI: 10.4061/2011/348960. View